Stocktoria

Xilio Therapeutics, Inc. XLO

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-10-22

Xilio Therapeutics, Inc. statistics & valuation

Market cap$49.4M
P / S1.1×
P / B1.4×
Net margin-80.1%
Return on equity-99.3%
FCF margin-12.6%
Return on capital-42.7%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-918.00% -80.10% 202020212022202320242025
Gross margin (%)
202020212022202320242025
Operating margin (%)
-954.90% -95.90% 202020212022202320242025
Return on equity (%)
-40.90% -83.50% -207.50% -331.00% -99.30% 202020212022202320242025
Shares outstanding
689929 27.4M 27.4M 27.6M 3.8M 8.4M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-152.00% -34.80% -63.40% -125.40% -81.90% -22.60% 202020212022202320242025
Free cash flow margin (%)
-290.30% -12.60% 202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$105.42 -$13.52 -$3.22 -$2.78 -$15.24 -$4.19 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-95.9%-954.9%————
Net margin-80.1%-918.0%————
FCF margin-12.6%-290.3%————
Return on assets-22.6%-81.9%-125.4%-63.4%-34.8%-152.0%
Return on equity-99.3%-331.0%-207.5%-83.5%-40.9%66.3%
Current ratio2.582.213.025.8915.850.93

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.